EI
KYNB

EAM Investors’s Kyntra Bio KYNB Stock Holding History

EAM Investors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,190
Closed -$2.95M – 313
2017
Q3 		$2.95M Buy
+2,190
New +$2.31M 0.39% 72
2016
Q2 		– Sell
-4,860
Closed -$2.59M – 323
2016
Q1 		$2.59M Sell
4,860
-403
-8% -$201K 0.4% 106
2015
Q4 		$4.01M Buy
5,263
+1,607
+44% +$1.07M 0.52% 44
2015
Q3 		$2M Buy
+3,656
New +$2.21M 0.32% 145

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM Investors's KYNB Position: Q4 2017 in Review

EAM Investors sold out of Kyntra Bio (KYNB) in Q4 2017, closing a stake of 2,190 shares — an estimated $2.95M sold.

EAM Investors first reported a position in KYNB in Q3 2015 and held it in 4 quarters. The position peaked at $4.01M in Q4 2015. 187 funds tracked by Wall St. Rank hold KYNB as of Q4 2017.

  • EAM Investors reported no remaining Kyntra Bio position as of Q4 2017 after selling out during the quarter.
  • EAM Investors sold 2,190 Kyntra Bio shares in Q4 2017, an estimated $2.95M.
  • EAM Investors first reported a position in Kyntra Bio in Q3 2015 and held it in 4 quarters.
  • EAM Investors's Kyntra Bio position peaked at $4.01M in Q4 2015.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.